Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	434.43	60	26.58	27.36	28.63
Revenue Growth (YoY)	624.05%	125.72%	-2.84%	-4.44%	12293.07%
Gross Profit	434.43	60	26.58	27.36	28.63
Selling, General & Admin	43.46	33.49	31.74	27.2	18.64
Research & Development	138.13	120.16	126.22	126.01	74.51
Operating Expenses	181.59	153.65	157.95	153.2	93.14
Operating Income	252.84	-93.65	-131.37	-125.85	-64.52
Interest Expense	-	-	-	-	-0.6
Interest & Investment Income	26.32	14.9	4.06	0.44	0.9
Currency Exchange Gain (Loss)	0.25	-0.2	-0.08	-0.15	-0.05
EBT Excluding Unusual Items	279.41	-78.96	-127.39	-125.55	-64.26
Other Unusual Items	-	-	-	-	-0.59
Pretax Income	279.41	-78.96	-127.39	-125.55	-64.85
Income Tax Expense	4.22	-	-	-	1.31
Net Income	275.19	-78.96	-127.39	-125.55	-66.15
Net Income to Common	275.19	-78.96	-127.39	-125.55	-66.15
Shares Outstanding (Basic)	62	57	49	46	34
Shares Outstanding (Diluted)	65	57	49	46	34
Shares Change (YoY)	14.65%	15.74%	5.87%	34.67%	32.84%
EPS (Basic)	4.47	-1.39	-2.60	-2.71	-1.92
EPS (Diluted)	4.23	-1.39	-2.60	-2.71	-1.92
Free Cash Flow	182.8	-70.85	-108.93	-108.97	-72.96
Free Cash Flow Per Share	2.81	-1.25	-2.22	-2.35	-2.12
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	58.20%	-156.09%	-494.24%	-460.01%	-225.36%
Profit Margin	63.34%	-131.59%	-479.26%	-458.94%	-231.07%
Free Cash Flow Margin	42.08%	-118.08%	-409.81%	-398.31%	-254.84%
EBITDA	253.67	-92.68	-130.34	-125.03	-63.57
EBITDA Margin	58.39%	-154.46%	-	-	-222.05%
D&A For EBITDA	0.83	0.98	1.03	0.81	0.95
EBIT	252.84	-93.65	-131.37	-125.85	-64.52
EBIT Margin	58.20%	-156.09%	-	-	-225.36%
Effective Tax Rate	1.51%	-	-	-	-

Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q